April 8 (Reuters) - Beigene Ltd 6160.HK :
* BEIGENE PROVIDES UPDATE ON PHASE 2 CLINICAL TRIAL OF ZANUBRUTINIB IN PATIENTS WITH COVID-19-RELATED PULMONARY DISTRESS
* BEIGENE LTD - TRIAL DID NOT MEET CO-PRIMARY EFFICACY ENDPOINTS; NO NEW SAFETY SIGNALS IDENTIFIED
* BEIGENE LTD - THERE WERE NO NEW OR ADDITIONAL SAFETY SIGNALS FOR ZANUBRUTINIB IDENTIFIED IN TRIAL
Source text for Eikon: Further company coverage: